Evaluating the in vivo effect of potential drugs for the treatment of Arthritis

• Grant number: 17/04936-1
• Support type: Scholarships in Brazil - Post-Doctorate
• Effective date (Start): May 01, 2017
• Effective date (End): April 30, 2019
• Field of knowledge: Biological Sciences - Pharmacology - General Pharmacology
• Principal researcher: José Carlos Farias Alves Filho
• Grantee: Talita Perdigão Domiciano
• Home Institution: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil
• Associated research grant: 13/08216-2 - CRID - Center for Research in Inflammatory Diseases, AP.CEPID

Abstract

Inflammatory diseases are a complex and heterogeneous group of diseases that causes morbidity and mortality and represent an important socioeconomic problem. The mission of the Center of Research in Inflammatory Diseases (CRID) is to perform translational research, basic and clinical research in the area of inflammatory diseases. In the last years several studies in CRID labs have characterized the role of some molecules in the pathophysiology of inflammatory diseases. Based on these targets, one aim of CRID is to plan/design (in silico WP3) and to test (in vitro, WP5) novel compounds able to interact selectively with these targets. Among the targets characterized by CRID, we have already characterized the role of Aryl hydrocarbon Receptor (AhR) as an important player in the pathogenesis of Rheumatoid Arthritis (RA). Moreover, we have also reported that fructose-1,6-bisphosphate (FBP), a glycolytic metabolite, as a compound with very promisor anti-inflammatory effect in experimental arthritis. In silico and in vitro studies conducted by CRID have identified and provided candidates for evaluation of the in vivo modulatory effect in their respective pharmacological effects. In this sense, the present activity plan has as main objective to evaluate the modulating effect of the Aromatic hydrocarbon Receptor (AhR) and determine the effect of a nanocapsule formulation loaded with FBP in the experimental models of Zymosan-Induced Arthritis (ZIA) and Antigen-Induced Arthritis (AIA). (AU)